Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial (Q104791927)
Jump to navigation
Jump to search
scientific article published on 01 January 2021
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial |
scientific article published on 01 January 2021 |
Statements
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial (English)
Kristin B Highland
Oliver Distler
Masataka Kuwana
Yannick Allanore
Shervin Assassi
Arata Azuma
Arnaud Bourdin
Christopher P Denton
Jörg H W Distler
Anna Maria Hoffmann-Vold
Dinesh Khanna
Maureen D Mayes
Ganesh Raghu
Madelon C Vonk
Martina Gahlemann
Emmanuelle Clerisme-Beaty
Mannaig Girard
Susanne Stowasser
Donald Zoz
Toby M Maher
SENSCIS trial investigators
1 January 2021